These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 29774589)

  • 1. Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database.
    Allen AM; Van Houten HK; Sangaralingham LR; Talwalkar JA; McCoy RG
    Hepatology; 2018 Dec; 68(6):2230-2238. PubMed ID: 29774589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.
    Terai S; Buchanan-Hughes A; Ng A; Lee IH; Hasegawa K
    J Gastroenterol; 2021 Mar; 56(3):274-284. PubMed ID: 33496858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic fatty liver disease: impact on healthcare resource utilization, liver transplantation and mortality in a large, integrated healthcare system.
    Cotter TG; Dong L; Holmen J; Gilroy R; Krong J; Charlton M
    J Gastroenterol; 2020 Jul; 55(7):722-730. PubMed ID: 32328797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.
    Romero-Gomez M; Kachru N; Zamorano MA; Darba J; Shreay S
    Medicine (Baltimore); 2020 Dec; 99(50):e23506. PubMed ID: 33327291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy.
    Petta S; Ting J; Saragoni S; Degli Esposti L; Shreay S; Petroni ML; Marchesini G;
    Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):1014-1022. PubMed ID: 32423665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
    Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
    Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA.
    Nguyen AL; Park H; Nguyen P; Sheen E; Kim YA; Nguyen MH
    Dig Dis Sci; 2019 Mar; 64(3):698-707. PubMed ID: 30327963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease Among Hospitalized Adults in the United States.
    Hirode G; Vittinghoff E; Wong RJ
    J Clin Gastroenterol; 2019; 53(10):765-771. PubMed ID: 31135632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing Health Care Utilization, Direct Costs, and Comorbidities Associated with Interstitial Cystitis: A Retrospective Claims Analysis.
    Tung A; Hepp Z; Bansal A; Devine EB
    J Manag Care Spec Pharm; 2017 Apr; 23(4):474-482. PubMed ID: 28345436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database.
    Prescott JD; Factor S; Pill M; Levi GW
    J Manag Care Pharm; 2007; 13(1):44-52. PubMed ID: 17269836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.
    Younossi ZM; Blissett D; Blissett R; Henry L; Stepanova M; Younossi Y; Racila A; Hunt S; Beckerman R
    Hepatology; 2016 Nov; 64(5):1577-1586. PubMed ID: 27543837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health Care Resource Utilization and Cost Before Initial Schizophrenia Diagnosis.
    Wallace A; Barron J; York W; Isenberg K; Franchino-Elder J; Sidovar M; Sand M
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1102-1110. PubMed ID: 31556820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare resource utilization and costs by disease severity in an insured national sample of US patients with chronic hepatitis B.
    Nguyen MH; Burak Ozbay A; Liou I; Meyer N; Gordon SC; Dusheiko G; Lim JK
    J Hepatol; 2019 Jan; 70(1):24-32. PubMed ID: 30287341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in outpatient resource utilizations and outcomes for Medicare beneficiaries with nonalcoholic fatty liver disease.
    Younossi ZM; Zheng L; Stepanova M; Henry L; Venkatesan C; Mishra A
    J Clin Gastroenterol; 2015 Mar; 49(3):222-7. PubMed ID: 24637730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases.
    Wong RJ; Kachru N; Martinez DJ; Moynihan M; Ozbay AB; Gordon SC
    J Clin Gastroenterol; 2021 Nov-Dec 01; 55(10):891-902. PubMed ID: 32815873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.
    Estes C; Razavi H; Loomba R; Younossi Z; Sanyal AJ
    Hepatology; 2018 Jan; 67(1):123-133. PubMed ID: 28802062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health Care Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease Are Nearly Twice Those of Matched Controls.
    Hagström H; Nasr P; Ekstedt M; Hammar U; Widman L; Stål P; Hultcrantz R; Kechagias S; Henriksson M
    Clin Gastroenterol Hepatol; 2020 Jun; 18(7):1592-1599.e8. PubMed ID: 31634581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
    Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
    J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
    Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
    J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evaluation of costs of illness for pneumonia in adult patients in Dubai-A claims database study.
    Al Dallal SAM; Farghaly M; Ghorab A; Elaassar M; Haridy H; Awad N; Chickballapur Ramachandrachar B; Natarajan A
    PLoS One; 2021; 16(9):e0256856. PubMed ID: 34469441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.